J&J Unit Keeps Generic Cos. At Bay Over Risperdal

Law360, New York (October 16, 2006, 12:00 AM EDT) -- Blocking two proposed generic versions of an antipsychotic drug, a New Jersey district court has affirmed the validity and enforceability of a Johnson & Johnson unit’s patent for Risperdal.

Judge John C. Lifland of the U.S. District Court for the District of New Jersey approved Janssen’s bid for an injunction against Mylan Pharmaceuticals Inc. and Dr. Reddy’s Laboratories Ltd. from selling their generic copycats of the drug in the United States until Janssen’s patent expires in late 2007.

Lifland ordered the U.S. Food and Drug Administration...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.